Moreover, the ongoing phase 2 Neo-DIANA study (NCT04512430) is evaluating the efficacy of the combination regimen of neoadjuvant PD-L1 blockade, atezolizumab, chemotherapy, and antiangiogenic agents in EGFR-mutant locally advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.